Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent

Rigosertib is a small molecule in preclinical development that, due to its characteristics as a dual PLK1 and PI3K inhibitor, is particularly effective in counteracting the advance of different types of tumors. In this work, we evaluated the efficacy of Rigosertib and the expression of p53 in five d...

Descripción completa

Detalles Bibliográficos
Autores principales: Malacrida, Alessio, Deschamps-Wright, Marie, Rigolio, Roberta, Cavaletti, Guido, Miloso, Mariarosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866497/
https://www.ncbi.nlm.nih.gov/pubmed/36675237
http://dx.doi.org/10.3390/ijms24021721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866497/
https://www.ncbi.nlm.nih.gov/pubmed/36675237
http://dx.doi.org/10.3390/ijms24021721

Ejemplares similares